Welcome to our dedicated page for Rein Therapeutics news (Ticker: RNTX), a resource for investors and traders seeking the latest updates and insights on Rein Therapeutics stock.
Rein Therapeutics, Inc. (NASDAQ: RNTX) is a clinical-stage biopharmaceutical company focused on first-in-class therapies for idiopathic pulmonary fibrosis (IPF) and other orphan pulmonary and fibrosis indications. The RNTX news feed highlights company announcements, scientific publications, regulatory updates, clinical milestones, and financing developments that shape the outlook for its pipeline.
Investors and observers can follow detailed updates on LTI-03, Rein’s lead Caveolin-1–related peptide candidate for IPF. Recent news has covered initiation and progress of the global Phase 2 RENEW trial, including first patient dosing, regulatory authorizations from the U.K. MHRA and the European Medicines Agency for sites in the United Kingdom, Germany, and Poland, and the U.S. Food and Drug Administration’s decision to lift a full clinical hold on the U.S. portion of the study.
The news stream also features translational and clinical science, such as peer-reviewed and preprint publications describing LTI-03’s anti-fibrotic activity in ex vivo lung tissue from IPF patients and inhaled dose-escalation studies assessing safety, pharmacokinetics, and biomarker changes. These reports discuss reductions in fibrosis-associated biomarkers, effects on multiple scarring pathways, and preservation of alveolar epithelial type II progenitor cells.
Additional coverage includes updates on LTI-01 for loculated pleural effusions, corporate and governance events such as annual meeting notices and adjournments, and capital markets activity, including pre-paid advance and standby equity purchase agreements and their subsequent termination. By reviewing RNTX news, readers can track how Rein Therapeutics communicates clinical progress, regulatory interactions, and strategic financing decisions that influence its development programs.
Rein Therapeutics (NASDAQ:RNTX) closed a $57.5 million underwritten public offering of common stock, including full exercise of the underwriters’ over-allotment option.
The company sold 57.5 million shares at $1.00, with no warrants, and expects proceeds to fund its Phase 2 LTI-03 IPF trial and operations into Q1 2028.
Rein Therapeutics (NASDAQ: RNTX) priced an underwritten public offering of 50.0 million common shares at $1.00 per share for gross proceeds of $50 million, with a 45‑day option to purchase up to an additional 7.5 million shares. The offering is expected to close on or about May 4, 2026.
Rein intends to use net proceeds to fully fund its ongoing Phase 2 trial of LTI‑03 in idiopathic pulmonary fibrosis and for working capital; it believes proceeds plus cash on hand will fund operations into 2028.
Rein Therapeutics (NASDAQ: RNTX) provided a Phase 2 RENEW trial update for LTI-03 in idiopathic pulmonary fibrosis. Enrollment began in March 2026; the study has enrolled 8 patients with 2 additional patients expected this week.
Clinical sites are active in the United States, Australia, and Poland, and the company expects to open sites in the United Kingdom and Germany soon to support ongoing enrollment.
Rein Therapeutics (NASDAQ:RNTX) has dosed the first patient in a randomized, double-blind, placebo-controlled Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis (IPF) after the FDA cleared the company to resume the program.
The trial will enroll ~120 patients across placebo, low and high dose groups in five countries, expects enrollment through mid-2027, and anticipates interim data in H2 2026. Initial activity is at five U.S. sites with planned expansion up to 50 sites.
Rein Therapeutics (NASDAQ:RNTX) announced that the European Commission granted orphan drug designation to its lead candidate LTI-03 for idiopathic pulmonary fibrosis (IPF) on Jan 20, 2026.
The decision follows a positive COMP opinion and was supported by preclinical data showing improved survival and lung function. The EU designation (No. EU/3/25/3188) recognizes the seriousness of IPF and may provide regulatory incentives including reduced development fees, potential market exclusivity after approval, and streamlined regulatory interactions to aid clinical development.
Rein Therapeutics (NASDAQ: RNTX) reported a new medRxiv preprint (Nov 6, 2025) describing an inhaled, randomized dose‑escalation study of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients.
The authors reported that LTI-03 was generally well tolerated, showed reductions in multiple fibrosis‑associated biomarkers, and appeared to preserve alveolar epithelial type II (AT2) progenitor cells, which are important for lung repair. Investigators said the data indicate lung target engagement and support continued development in the ongoing global Phase 2 RENEW trial.
Rein Therapeutics (NASDAQ: RNTX) announced that the U.S. Food and Drug Administration has lifted the full clinical hold on its Phase 2 RENEW trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) after reviewing Rein’s complete response submission.
The company expects to resume U.S. enrollment in late 2025 or early 2026 across ~20 U.S. sites, complementing ~30 global sites. The study will enroll up to 120 patients, assess safety, tolerability and efficacy with key secondaries including FVC and imaging measures, and plans initial topline data in Q3 2026. Rein stated early data suggest LTI-03 may slow fibrosis and support lung repair.
Rein Therapeutics (NASDAQ: RNTX) announced EMA authorization on Oct 9, 2025 to start its global Phase 2 RENEW trial of LTI-03 for idiopathic pulmonary fibrosis (IPF).
The EMA approval covers study sites in Germany and Poland; the company previously received clearance from the U.K. MHRA. LTI-03 is described as a first-in-class therapy intended to both reduce lung scarring and promote tissue repair. The approvals position Rein to begin multi-region patient enrollment and advance its lead candidate through Phase 2.
Rein Therapeutics (NASDAQ: RNTX) has published new data in iScience demonstrating the potential of its lead drug candidate LTI-03 in treating Idiopathic Pulmonary Fibrosis (IPF). The study, conducted on actual lung tissue from IPF patients, showed that LTI-03 effectively reduced multiple scarring pathways and lowered collagen production without causing cell damage, unlike the current FDA-approved treatment nintedanib.
The research supports Rein's ongoing Phase 2 RENEW trial, which will evaluate LTI-03 in up to 120 IPF patients, with initial data expected in 2026. IPF affects approximately 100,000 people in the U.S. and 70,000 in the U.K., with the global treatment market projected to exceed $11 billion by 2031.
Rein Therapeutics (NASDAQ: RNTX) has received approval from the UK's MHRA to begin its Phase 2 "RENEW" clinical trial for LTI-03, a first-in-class therapy targeting idiopathic pulmonary fibrosis (IPF). The trial will evaluate 120 patients across two dose groups against placebo, with initial data expected in 2026.
LTI-03 is designed to target fibrosis while protecting lung regeneration capability, potentially offering a breakthrough treatment for IPF, a serious lung disease with a median survival of just 3-5 years after diagnosis. The 24-week trial will primarily assess safety and tolerability, with secondary endpoints including lung function and fibrosis progression measures.